NovellusDx announced that the Chinese Patent Office granted it a patent for: “Methods and systems for identifying patient-specific driver mutations”. This approval comes after receiving a similar approval from the American and the European patent offices earlier this year and protects the innovative advantage of the technology developed by NovellusDx. The patent, the first of a large patent family, is fully owned by the company and protects its core technology and shall remain in force for 20 years from the international filing date of the application, i.e. until January 15, 2034.
The methods disclosed in the patent relate to the identification of functionally important mutations of the patient using the FACT test.
“This patent is part of our main patent family”, says Dr. Tarcic, “and protects the main kernel of our system to identify driver mutations by examining their effect in live cells”.